Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 767

1.

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ.

Neurobiol Dis. 1996 Feb;3(1):16-32.

PMID:
9173910
2.

Intraneuronal Abeta42 accumulation in Down syndrome brain.

Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA.

Amyloid. 2002 Jun;9(2):88-102.

PMID:
12440481
3.

Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome.

Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DM, Tabaton M, Gambetti P.

Nat Med. 1996 Jan;2(1):93-5.

PMID:
8564851
5.

Variability of beta-amyloid protein deposited lesions in Down's syndrome brains.

Ikeda S, Tokuda T, Yanagisawa N, Kametani F, Ohshima T, Allsop D.

Tohoku J Exp Med. 1994 Nov;174(3):189-98.

6.

Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype.

Hyman BT, West HL, Rebeck GW, Lai F, Mann DM.

Arch Neurol. 1995 Apr;52(4):373-8.

PMID:
7710373
7.
8.

Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease.

Dickson TC, Saunders HL, Vickers JC.

Neuropathol Appl Neurobiol. 1997 Dec;23(6):483-91.

PMID:
9460714
9.
11.
12.

Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.

Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA.

Am J Pathol. 2000 Feb;156(2):489-99.

13.
14.

The impact of risk factors of Alzheimer's disease in the Down syndrome.

Folin M, Baiguera S, Conconi MT, Pati T, Grandi C, Parnigotto PP, Nussdorfer GG.

Int J Mol Med. 2003 Feb;11(2):267-70.

PMID:
12525890
15.

Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly.

Walker LC, Pahnke J, Madauss M, Vogelgesang S, Pahnke A, Herbst EW, Stausske D, Walther R, Kessler C, Warzok RW.

Acta Neuropathol. 2000 Jul;100(1):36-42.

PMID:
10912918
16.

Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.

Russo C, Salis S, Dolcini V, Venezia V, Song XH, Teller JK, Schettini G.

Neurobiol Dis. 2001 Feb;8(1):173-80. Erratum in: Neurobiol Dis 2001 Jun;8(3):540.

PMID:
11162251
17.
18.

Distribution of beta/A4 protein and amyloid precursor protein in hereditary cerebral hemorrhage with amyloidosis-Dutch type and Alzheimer's disease.

Rozemuller AJ, Roos RA, Bots GT, Kamphorst W, Eikelenboom P, Van Nostrand WE.

Am J Pathol. 1993 May;142(5):1449-57. Review.

19.

Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease.

Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA.

Acta Neuropathol. 1999 Feb;97(2):113-8.

PMID:
9928821
20.

Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains.

Hosoda R, Saido TC, Otvos L Jr, Arai T, Mann DM, Lee VM, Trojanowski JQ, Iwatsubo T.

J Neuropathol Exp Neurol. 1998 Nov;57(11):1089-95.

PMID:
9825946

Supplemental Content

Support Center